# ctHPV-DNA-adapted de-escalation of chemoradiation

Source: https://onco.cc/ideas/idea-cthpv-adapted-deescalation/  
OnCo record `idea-cthpv-adapted-deescalation` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Instead of guessing from HPV status who can get less radiation, measure the virus DNA in blood during treatment and reduce dose only when it clears fast.

## Summary

The idea is to reduce the radiation dose in HPV-positive head and neck cancer only for patients whose circulating tumour HPV DNA clears quickly during treatment, rather than for everyone who is HPV-positive. NRG-HN005 showed that static selection on HPV status fails, whereas ctHPV-DNA kinetics track tumour kill in real time and outperform baseline staging for predicting recurrence. The hypothesis is that patients whose ctHPV-DNA clears by week 2 to 3 of chemoradiation can receive 60 Gy without loss of progression-free survival, while non-clearers receive the full 70 Gy. The test is a phase 2/3 trial of ctHPV-DNA-guided dose versus uniform 70 Gy, with progression-free survival and quality of life as endpoints; the idea sits on the radiotherapy roadmap.

## Fields

- Kind: Idea
- Last checked: 2026-09-07
- Hypothesis: Patients whose ctHPV-DNA clears by week 2-3 of chemoradiation can receive 60 Gy without loss of PFS, while non-clearers receive 70 Gy.
- Rationale: ctHPV-DNA kinetics track tumour kill in real time and outperform baseline staging for predicting recurrence.
- Proposed test: Phase 2/3 with ctHPV-DNA-guided dose assignment versus uniform 70 Gy; PFS non-inferiority in clearers and quality-of-life superiority.
- Maturity: early-clinical

## Sources

- ClinicalTrials.gov NCT03952585: NRG-HN002 & NRG-HN005 (HPV+ de-escalation): https://clinicaltrials.gov/study/NCT03952585

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HPV-positive oropharyngeal cancer](https://onco.cc/cancers/hpv-positive-oropharyngeal-cancer/)
- technologies: [Circulating tumour HPV DNA (ctHPV-DNA)](https://onco.cc/technologies/cthpv-dna/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [HPV-positive (p16) head and neck cancer](https://onco.cc/terms/hpv-p16/)
- trials: [NRG-HN002 & NRG-HN005 (HPV+ de-escalation)](https://onco.cc/trials/nrg-hn002-hn005/)
- roadmaps: [Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH](https://onco.cc/roadmaps/radiation-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-cthpv-adapted-deescalation.json